Association of angiopoietin-2 and Ki-67 expression with vascular density and sunitinib response in metastatic renal cell carcinoma

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Rautiola, Juhana ^a   Lampinen, Anita ^b   Mirtti, Tuomas ^d   Ristimäki, Ari ^d   Joensuu, Heikki ^a   Bono, Petri ^a   Saharinen, Pipsa ^b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c WIHURI RESEARCH INSTITUTE   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CD31 ANTIGEN; KI 67 ANTIGEN; SUNITINIB; ANTINEOPLASTIC AGENT; C11ORF2 PROTEIN, HUMAN; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR MARKER; VESICULAR TRANSPORT PROTEIN;

ARTICLE; BLOOD VESSEL PARAMETERS; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; VASCULAR DENSITY; CANCER STAGING; CARCINOMA, RENAL CELL; ENZYME IMMUNOASSAY; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLES; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PYRROLES; SURVIVAL RATE; VESICULAR TRANSPORT PROTEINS;

EID: 84964762506     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153745     Document Type: Article

References (53)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373: 1119-1132. doi: 10.1016/S0140-6736(09)60229-4 PMID: 19269025
2. Ngo TC, Wood CG, Karam JA. Biomarkers of renal cell carcinoma. Urol Oncol. 2014; 32: 243-251. doi: 10.1016/j.urolonc.2013.07.011 PMID: 24239464
3. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011; 27: 563-584. doi: 10.1146/annurev-cellbio-092910-154002 PMID: 21756109
4. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013; 45: 860-867. doi: 10.1038/ng.2699 PMID: 23797736
5. McIntyre A, Harris AL. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med. 2015; 7: 368-379. doi: 10.15252/emmm.201404271 PMID: 25700172
6. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011; 108: 1556-1563. doi: 10.1111/j.1464-410X.2011.10629.x PMID: 21952069
7. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: iii49-56. doi: 10.1093/annonc/mdu259 PMID: 25210086
8. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, et al. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer. 2011; 104: 741-745. doi: 10.1038/sj.bjc.6606061 PMID: 21266975
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-3590. doi: 10.1200/JCO.2008.20.1293 PMID: 19487381
10. Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer. 2011; 11: 295. doi: 10.1186/1471-2407-11-295 PMID: 21756335
11. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer. 2012; 12: 699-709. doi: 10.1038/nrc3366 PMID: 23001349
12. Rigamonti N, Kadioglu E, Keklikoglou I, Wyser Rmili C, Leow CC, De Palma M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 2014; 8: 696-706. doi: 10.1016/j.celrep.2014.06.059 PMID: 25088418
13. Sounni NE, Cimino J, Blacher S, Primac I, Truong A, Mazzucchelli G, et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 2014; 20: 280-294. doi: 10.1016/j.cmet.2014.05.022 PMID: 25017943
14. Ravaud A, Schmidinger M. Clinical biomarkers of response in advanced renal cell carcinoma. Ann Oncol. 2013; 24: 2935-2942. doi: 10.1093/annonc/mdt288 PMID: 23925998
15. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res. 2013; 319: 1271-1280. doi: 10.1016/j.yexcr.2013.03.011 PMID: 23500414
16. Milam KE, Parikh SM. The angiopoietin-Tie2 signaling axis in the vascular leakage of systemic inflammation. Tissue Barriers. 2015; 3: e957508. doi: 10.4161/21688362.2014.957508 PMID: 25838975
17. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013; 328: 18-26. doi: 10.1016/j.canlet.2012.08.018 PMID: 22922303
18. Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013; 73: 1649-1657. doi: 10.1158/0008-5472.CAN-12-4697 PMID: 23467610
19. Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, et al. The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl Oncol. 2014; 7: 188-195. doi: 10.1016/j.tranon.2014.02.003 PMID: 24704536
20. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010; 70: 2213-2223. doi: 10.1158/0008-5472.CAN-09-1977 PMID: 20197469
21. Holopainen T, Saharinen P, D'Amico G, Lampinen A, Eklund L, Sormunen R, et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst. 2012; 104: 461-475. doi: 10.1093/jnci/djs009 PMID: 22343031
22. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013; 73: 108-118. doi: 10.1158/0008-5472.CAN-12-2064 PMID: 23149917
23. Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res. 2013; 19: 6730-6740. doi: 10.1158/1078-0432.CCR-13-0081 PMID: 24097868
24. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells. Cancer Cell. 2011; 19: 512-526. doi: 10.1016/j.ccr.2011.02.005 PMID: 21481792
25. Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel SS, et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell. 2014; 26: 880-895. doi: 10.1016/j.ccell.2014.11.005 PMID: 25490450
26. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014.
27. Atkins MB, Gravis G, Drosik K, Demkow T, Tomczak P, Wong SS, et al. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. J Clin Oncol. 2015.
28. Sfiligoi C, de Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer. 2003; 103: 466-474. PMID: 12478661
29. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010; 103: 1407-1414. doi: 10.1038/sj.bjc.6605925 PMID: 20924372
30. Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014; 74: 739-750. doi: 10.1007/s00280-014-2539-0 PMID: 25100134
31. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res. 2009; 15: 1384-1392. doi: 10.1158/1078-0432.CCR-08-1615 PMID: 19228739
32. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005; 11: 2510-2517. PMID: 15814627
33. Tollefson MK, Thompson RH, Sheinin Y, Lohse CM, Cheville JC, Leibovich BC, et al. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer. 2007; 110: 783-790. PMID: 17594714
34. Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer. 2011; 11: 105. doi: 10.1186/1471-2407-11-105 PMID: 21435216
35. Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A, et al. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU Int. 2014; 113: 668-673. doi: 10.1111/bju.12263 PMID: 23937277
36. Keskin D, Kim J, Cooke VG, Wu CC, Sugimoto H, Gu C, et al. Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Rep. 2015; 10: 1066-1081. doi: 10.1016/j.celrep.2015.01.035 PMID: 25704811
37. Nakayama T, Yoshizaki A, Kawahara N, Ohtsuru A, Wen CY, Fukuda E, et al. Expression of Tie-1 and 2 receptors, and angiopoietin-1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors. Histopathology. 2004; 44: 232-239. PMID: 14987226
38. Demasi AP, Silva CA, Silva AD, Furuse C, Soares AB, Altemani A, et al. Expression of the vascular endothelial growth factor and angiopoietins in mucoepidermoid carcinoma of salivary gland. Head Neck Pathol. 2012; 6: 10-15. doi: 10.1007/s12105-011-0302-y PMID: 21948244
39. Li C, Fan J, Song X, Zhang B, Chen Y, Li C, et al. Expression of angiopoietin-2 and vascular endothelial growth factor receptor-3 correlates with lymphangiogenesis and angiogenesis and affects survival of oral squamous cell carcinoma. PLoS One. 2013; 8: e75388. doi: 10.1371/journal.pone.0075388 PMID: 24040410
40. Currie MJ, Gunningham SP, Turner K, Han C, Scott PA, Robinson BA, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol. 2002; 198: 502-510. PMID: 12434420
41. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999; 284: 1994-1998. PMID: 10373119
42. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med. 2006; 3: e46. PMID: 16417407
43. Kumpers P, van Meurs M, David S, Molema G, Bijzet J, Lukasz A, et al. Time course of angiopoietin-2release during experimental human endotoxemia and sepsis. Crit Care. 2009; 13: R64. doi: 10.1186/cc7866 PMID: 19416526
44. Conroy AL, Glover SJ, Hawkes M, Erdman LK, Seydel KB, Taylor TE, et al. Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study∗. Crit Care Med. 2012; 40: 952-959. doi: 10.1097/CCM. 0b013e3182373157 PMID: 22343839.
45. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, et al. The Tie-2 ligand angiopoietin- 2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004; 103: 4150-4156. PMID: 14976056.
46. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 2004; 93: 291-296. PMID: 14764125.
47. Yao X, Qian CN, Zhang ZF, Tan MH, Kort EJ, Yang XJ, et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res. 2007; 13: 161-169. PMID: 17200351.
48. Virman J, Bono P, Luukkaala T, Sunela K, Kujala P, Kellokumpu-Lehtinen PL. VEGFR3 and CD31 as prognostic factors in renal cell cancer. Anticancer Res. 2015; 35: 921-927. PMID: 25667475.
49. Dornbusch J, Zacharis A, Meinhardt M, Erdmann K, Wolff I, Froehner M, et al. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One. 2013; 8: e76386. doi: 10.1371/journal.pone.0076386 PMID: 24086736.
50. del Puerto-Nevado L, Rojo F, Zazo S, Carames C, Rubio G, Vega R, et al. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. Br J Cancer. 2014; 110: 2700-2707. doi: 10.1038/bjc.2014.225 PMID: 24786599.
51. Cheng SH, Liu JM, Liu QY, Luo DY, Liao BH, Li H, et al. Prognostic role of microvessel density in patients with renal cell carcinoma: a meta-analysis. Int J Clin Exp Pathol. 2014; 7: 5855-5863. PMID: 25337227.
52. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014; 46: 225-233. doi: 10.1038/ng.2891 PMID: 24487277.
53. Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, et al. The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res. 2013; 19: 6924-6934. doi: 10.1158/1078-0432.CCR-13-1631 PMID: 24130073